AstraZeneca's License Of Ionis NASH Candidate Illustrates Still Hot Competition
Along with last week's acquisition of three NASH candidates from Lilly by Terns, NASH remains a heavily crowded R&D space as the European Association for the Study of the Liver annual meeting approaches.
You may also be interested in...
TERN-101 showed a superior safety and tolerability profile for lipid levels and pruritis compared to other FXR agonists in a mid-stage study. Terns is now looking to a NASH combo study with its THR beta agonist.
In its third venture funding round, Terns adds backing from Deerfield in addition to Lilly’s investment. It licensed three non-alcoholic steatohepatitis candidates from the big pharma in 2018.
Terns raised an $80m Series B round for NASH and cancer programs, while 89Bio launched with a $60m Series A to fund drugs for NASH and other liver and metabolic diseases. Also, Stoke leads recent VC deals with $90m Series B.